AN OVERVIEW OF IMPLANTABLE DRUG DELIVERY SYSTEMS (IDDS): DEVICES AND ITS THERAPEUTIC APPLICATIONS

Poojan Diwan¹, Anjali Sharma¹, B. C. Nandy¹

¹Faculty of pharmaceutical Science, Jayoti Vidyapeeth Women’s University, Jaipur, Rajasthan, India.

ABSTRACT

In the past, drugs were frequently administered orally, as liquids or in powder forms incurred through the utilization of the oral route of drug administration, new dosage forms containing the drug(s) were introduced. As time progressed, there was a need for delivery systems that could maintain a steady release of drug to the specific site of action. Therefore, drug delivery systems were developed to optimize the therapeutic properties of drug products and render them more safe, effective, and reliable. Implantable drug delivery systems (IDDS) are an example of such systems available for therapeutic use. The study of currently available implantable drug delivery systems is the main focus of this review. The major advantages of these systems contain targeted local delivery of drugs at a constant rate, fewer drugs required to treat the disease state, minimization of probable side effects, and better efficacy of treatment. Due to the development of such sustained release formulations, it is now possible to administer unstable drugs once a week to once a year that in the past required frequent daily dosing. Preliminary studies using these systems have shown superior effectiveness over conventional methods of treatment. However, one limitation of these newly developed drug delivery systems is the fact that their cost-to-benefit ratio (cost/benefit) is too high which restricts their use over conventional dosage forms. Some of the most recently discovered implants are in the early developmental stages and more rigorous clinical testing is required prior to their use in standard practice.

Key Words: IDDS, Controlled Release, Injectable preparation.

INTRODUCTION

Orally administered drug must be protected against denaturation in the gastrointestinal tract and should be capable of absorption across the wall of the stomach or the intestine. After absorption and upon reaching the portal circulation, it must be resistant to hepatic enzymes. The rate of drug absorption and elimination should ensure the blood levels within the therapeutic range. Moreover, the amount of intact drug that reaches the site of action should be sufficiently large to obtain desired therapeutic effect but insufficient to cause untoward side effects. A controlled drug action may be achieved by either chemically modifying the drug moiety or by formulating it in a specific way to control its release. Oral controlled release dosage forms can provide efficacy for about 24 hours. The main drawback of oral dosage form is the long transit time of approximately 12 hours through the gastrointestinal tract (GIT). If drug cannot be administered orally, a parenteral route of delivery is an alternative. Many proteins/peptides and other drugs, which are susceptible to the adverse conditions of GIT may administered intravenously. Unfortunately, in intravenous drug administration, the duration of drug action is short for majority of therapeutically active agents and therefore frequent injections are required. The development of injectable controlled-release dosage forms is more likely to succeed commercially than alternative routes of delivery, assuming that these dosage forms provide the desired efficacy and safety. In case of topical drug administration, the percutaneous absorption of most drugs is limited due to physiological characteristics of the drugs and presence of highly impermeable stratum corneum. Implantable drug delivery devices are devoid of a limitations associated with oral, intravenous, topical drug administration vis-à-vis subcutaneously implantable drug delivery devices offer one unique advantage of a retrievable mechanism. Thus, more current implantables generally contain the therapeutic agent in a rate controlling systems. Implantables are available in various sizes and shapes. While oral delivery is considered the preferred method of administering many drugs, additional methods employing pulmonary, infusion, and implantable systems have been developed to overcome drug delivery constraints [1-3].

© www.albertscience.com, All Right Reserved.
For example, many macromolecules are either digested in the gastrointestinal tract or are not well absorbed into the bloodstream. Oral administration may also not be appropriate for drugs that require a rapid onset of action. Similarly, pulmonary systems such as inhalers require drugs to be absorbed into the bloodstream from the lungs. Drug delivery by injection has other disadvantages. Patients must choose between traveling to a treatment site and maintaining a home supply. Furthermore, the discomfort of frequent injections leads to poor patient compliance. Finally, a multiple, timed drug-injection regimen is complicated to administer and may require a clinician’s help. Portable infusion systems allow unassisted intravenous administration; however, these systems can only administer drugs in liquid form and require both a transcutaneous catheter and an external pump [1-4].

Over the last two decades, the field of controlled drug delivery has been faced with two major challenges. One has been achieving sustained zero-order release of a drug substance over a prolonged period of time. This goal has been met by a wide range of techniques, including osmotically driven pumps, matrices with controllable swelling diffusion or erosion rates, non-uniform drug loading profiles, and multi-layered matrices. The second of these challenges is the controlled delivery of a therapeutic molecule or protein in a schematic of a pulsatile or staggered fashion. Two different methodologies have been heavily investigated as possible solutions to these requirements. One is the fabrication of a delivery system that releases its payload at a predetermined time or in pulses of a predetermined sequence. The other is to develop a system that can respond to changes in the local environment. These systems have been shown to alter their rate of drug delivery in response to stimuli including the presence or absence of a specific molecule, magnetic fields, electric fields, ultrasound, light, temperature, and mechanical forces [4-6].

ADVANTAGES OF IMPLANTABLE DRUG DELIVERY SYSTEM [2-10]
The advantages of implantation therapy include:-
• Convenience:
Effective concentration of drug in the blood can be maintained for longer period of time by techniques such as continuous intravenous infusion or repeated injections. On the other hand, under these treatments patients are regularly required to visit hospital throughout administration for uninterrupted medical monitoring. A short-acting medicine worsens the condition, as the quantity of injections or the infusion rate need to be increased to maintain a therapeutically effective level of the drug.
• Improved drug delivery:
The drug is distributed locally or in systemic circulation with least interference by metabolic or biological barriers. For example, the drug moiety bypassed the GIT and the liver. The bypassing effect is beneficial to drugs, which are either easily inactivated or absorbed poorly in the GIT and/or the liver before systemic distribution.
• Compliance:
By allowing a reduction, or complete elimination, of patient-involved dosing compliance is increased hugely. Patient can forget to take a medicine, but drug delivery from an implant is not dependent of patient input. Periodical refilling is involved in some implantables but despite this limitation the patient has less involvement in delivering the required medication.
• Potential for controlled release:
Implants are available which deliver drugs by zero order controlled release kinetics. The advantages of zero order controlled release are:
(a) Peaks (toxicity) and troughs (ineffectiveness) of conventional therapy is avoided,
(b) Dosing frequency is reduced,
(c) Patient compliance is increased.
• Potential for bio-responsive release:
Bio-responsive release from implantable is an area of ongoing research.
• Potential for intermittent release:
Intermittent release can be facilitated by externally programmable pumps. Intermittent release can facilitate drug release in response to such factors as:
(a) Circadian rhythms,
(b) Fluctuating metabolic requirements,
(c) Pulsatile release of many peptides and proteins.

- **Flexibility:**
  In the choice of materials, methods of manufacture, degree of drug loading, drug release rate etc. considerable flexibility is possible. From a regulatory viewpoint, it is regarded as a new product and can lengthen the market protection of the drug for an additional 5 years (for a new drug entry) or 3 years (for existing drugs).

**DISADVANTAGES OF IMPLANTABLE DRUG DELIVERY SYSTEM [1-9]**

The disadvantages of implantables include:
- **Invasive:**
  To initiate therapy either a minor or a major surgical procedure is required to initiate therapy. Appropriate surgical personnel are required for this, and may be time-consuming, traumatic. This causes some scar formation at the site of implantation and surgery related complications in a very small number of patients. Uncomfortable feeling for the patient wearing the device-
- **Danger of device failure:**
  There is no associated danger with this treatment that the device may for some reason fail to work. This again requires surgical involvement to correct.
- **Termination:**
  Osmotic pumps and non-biodegradable polymeric implants also are surgically recovered at the end of therapy. Although surgical recovery is not required in biodegradable polymeric implants. Its on-going biodegradation makes it difficult to end drug delivery, or to maintain the accurate dose at the end of its lifetime.
- **Limited to potent drugs:**
  In order to minimize patient’s discomfort the size of an implant is usually kept small. Therefore most implants have a limited loading capacity so that frequently only somewhat potent medicines such as hormones may be appropriate for delivery by implantable devices [1].

- **Biocompatibility issues:**
  Concerns over body reactions to a foreign substance often increase the issues of biocompatibility and safety of an implant.
- **Possibility of adverse reactions:**
  A high concentration of the drug delivered by an implantable device at the implantation site may produce adverse reactions [10-14].
- **Commercial disadvantage**
  An enormous amount of R&D investment, effort and time is required in the development on an IDDS. If a new material is proposed to formulate an implant its incompatibility and safety must be carefully evaluated to secure the approval of regulatory organisations. These issues can attribute to noteworthy delay in the progress, marketing and price of a new implant [15].

**IMPLANTABLE DRUG DELIVERY DEVICES**

- **Field of Controlled Drug Delivery**
  Implantable controlled drug delivery methods are also useful to deliver medication to those parts of the body which are immunologically isolated and regular modes of drug delivery cannot reach them, for example, the cornea. The field of controlled drug delivery today employs mechanisms such as transdermal patches, polymer implants, bioadhesive systems, and microencapsulation.

- **Transdermal Patches**
  Transdermal patches generally have hollow micro needles made of a biocompatible polymer through which the drug is delivered below the skin. Transdermal patches have numerous advantages compared with other systems of drug delivery: the drugs are not degraded in the GIT, they are painless, and they deliver a constant dosage without the need for patient’s compliance. A renowned example for transdermal patches is the nicotine patch.

- **Polymer Implants**
  Polymer implants are biodegradable polymers loaded with the drug molecules. The polymer degrades when it comes in interaction with body fluids and in the process releases drug molecules. The rate of degradation of the polymer, and hence the drug release, can be optimized by modifying the properties of the polymers. The polymer material which are most widely used for these application include, but are not restricted to, Polyglycolic acid(PGA), Polylactic acid(PLA), Polyurethane and the combinations of these in different proportions.

- **Bioadhesives**
  Bioadhesives are substances which form bonds with biological surfaces. The most common substances which are used in this case are polymer hydrogels. The principle of operation is similar to polymer implants in this that they too are loaded with drugs and release drugs at a specific rate when in contact with body fluids. Hydrogels are water-swollen polymer networks. The polymer chains may be held together by either physical forces or covalent crosslinks. By design of the hydrogel constituents, they can be made responsive to their chemical or physical environment. At a temperature of 35-40 ºC it collapses into a denser, more compact structure due to a switch in the balance of solution and hydrophobic forces as the temperature is raised [4].

- **Microencapsulation**
  Microencapsulation refers to the method of covering the drug molecule with a material which will prolong the time before the drug is absorbed, so that it will remain in the viable state and will be released when it reaches the intended destination. There are variety of ways in which microencapsulation is done. Some of them are use of polymer microspheres, liposomes, nanoparticles etc. The above devices are ‘passive devices’ and deliver the drug gradually in very small amounts with precision. But they are not capable of delivering the drug in a non-linear fashion or ‘on demand’. They cannot be programmed to deliver drug when required and stop when not required.

**Some Important Passive Devices**

- **Microchip Drug Reservoirs**
  These devices came out of the lab of Dr. Robert Langer lab at MIT. It is one of the very first truly Micro Electro Mechanical Systems (MEMS) based drug delivery systems. The design incorporates multiple sealed compartments, which are opened on demand to deliver dose of a drug. Fabrication of these microchips began by depositing, 0.12
mm of low stress, silicon nitride on both sides of prime grade (100) silicon wafers using a vertical tube reactor. The silicon nitride layer on one side of the wafer was patterned by photolithography and electron cyclotron resonance (ECR) enhanced reactive ion etching (RIE) to give a square device (17mm x 3mm x 17 mm) containing 34,480 square reservoirs. The silicon nitride served as an etch mask for potassium hydroxide solution at 85.8°C, which an iso-tropically etched square pyramidal reservoirs into the silicon along the crystal planes until the silicon nitride on the opposite side of the wafer was reached.

Figure 2: Microchip drug reservoir.

- **Immuno-isolating Capsules**
  These devices are not drug delivery systems in the conventional sense. They deliver insulin in the body but rather than store it in the device they contain pancreatic islet cells which make insulin and deliver through the nanoporous membrane of the device. Microfabrication techniques have been applied to create a biocapsule for effective immunoisolation of transplanted islet cells for the treatment of diabetes. The fabrication of nanochannels in the membrane structure consists of two steps. First, surface micromachining nanochannels in a thin film on the top of a silicon wafer. Second, releasing the membrane by etching away the bulk of the silicon wafer underneath the membrane. These nanopore membranes are designed to allow the permeability of glucose, insulin, and other metabolically active products, while at the same time, preventing the passage of cytotoxic cells, macrophages, and complement. The membranes are bonded to a capsule that houses the pancreatic islet cells.

- **Diffusion Chambers**
  It is a diffusion chamber from Debiotech Inc. They hold a cargo of drugs and are sealed with a semi-permeable membrane. These are used for delivering fairly large amount of drugs and in some cases more than one drug. The membrane surface area is large compared to the reservoir resulting in the increased delivery rates. These reservoirs are generally not used for long term delivery.

- **Diffusion Controlled Implanted Tubes**
  These use a narrow aperture to provide a slow delivery rate of drugs. They are used for long-term release of highly potent drugs, with the release times it the order of years. A good example is the five-year duration birth control implants based on elastomeric tubes. A similar example is that of the Duros TM osmotic pump from ALZA Corporation. This non biodegradable, osmotically driven system is intended to enable delivery of small drugs, peptides, proteins, DNA and other bioactive macromolecules for systemic or tissue-specific therapy. The DUROS implant is a miniature cylinder made from a titanium alloy, which protects and stabilizes the drug inside, using ALZA's proprietary formulation technology. Water enters into one end of the cylinder through a semi-permeable membrane; the drug is delivered from a port at the other end of the cylinder at a controlled rate suitable to the specific therapeutic agent. The delivery can be over a period of 12 months [11-16].

Figure 3: Duros osmotic pump

Why Implantable Devices For Drug Delivery?
Implantable drug delivery devices offer several advantages over conventional oral or parenteral dosage form. First implantable devices allow site specific drug administration where the drug is needed most. Examples include implants used in the treatment of brain tumors or prostate cancer. This may also allow for significantly lower doses of the drug which can minimize potential side effects. Second, implantable devices allow for sustained release for therapeutic agent. The last and perhaps most important advantage is patient compliance, as a treatment regimen associated with an implantable device is generally less burdensome than pills or injection.

Opportunities in Women’s Health
In addition to subcutaneous implants, novel drug delivery forms, such as intrauterine devices (IUDs) and intra-vaginal rings (IVRs) are finding increasing applications in the area of women’s health. In 2000, the FDA approved a levo-norgesterel eluting IUD providing contraception for up to five years of use. Later, the use of device was expanded to include an indication for severe menstural bleeding; a smaller device was approved for women who have not had children. IVRs are commercially available for contraception, hormone replacement therapy and to improve the rate of in vitro fertilization (in development) [16].

Figure 4: IUDs

THE IDDS SYSTEM

• Conceptual Design
The IDDS system proposed in this thesis has the following components:

 a) Micropump
 b) Reservoir
 c) Power Module
 d) Control Circuitry and RF Telemetry

 a) Micropump
The micropump is an on-demand active device that can be electrically controlled to deliver specific volumes of therapeutic agents. The micropump provides the driving mechanism to deliver the drug from the reservoir to the catheter. The requirements for drug delivery include small size and high reliability. The IDDS should be capable of delivering drugs against a back pressure of blood in the range of 8mm Hg to 12mm Hg in the veins or greater than 120mmHg in the arteries. The IDDS uses an ‘in-plane’ silicon pump fabricated from silicon on- insulator (SOI) wafer by deep reactive ion etching (DRIE) process [15-19].

 b) Reservoir
The reservoir plays an important role in determining the size of the implantable device. Our reservoir is similar in design to the vascular access ports. These ports have been demonstrated to have good bio-stability and biocompatibility [14]. The reservoir should have smooth contours, hold at least 5 ml of the drug and be easily accessible for refilling. A subcutaneous position for the port-like reservoir was chosen for the IDDS. The size of the reservoir can be varied based on need at the same time retaining the size of the pump. For reasons of biocompatibility, titanium or silicone reservoir will be used. It must be noted that there is no set dosage for continuous infusion for chemotherapy. The dosage, infusion rate and drug combination can vary depending on the treatment requirements. The port is connected to the implantable unit via a catheter.

c) Power Management
Without taking into account the power required by the RF unit, the estimated power consumption for the target 10 μl/min delivery rate is in the range of 100-500 mW. This figure is estimated based on the power consumption of the micropump necessary to generate required diaphragm displacements. As a result, commercially available miniature lithium-ion batteries would discharge in less than 48 hours continuous operation. Therefore, a power management system employing recharging of the power source is necessary in the IDDS. One possibility is recharging from outside of the body using through-skin electrical interconnects. A much better alternative would be wireless power transmission using RF coils.

 d) Control and Telemetry Circuitry
In figure 4 the telemetry test setup is placed 5m apart. The transmitted signal is a 1.2 mV p-amplified by a factor of 2000 and received signal is 191 mV. The modulated signal is a 1 kHz sine wave with a 433 MHz carrier. The telemetry module consists of a transmitter unit and a receiver unit. Our goal is to integrate the telemetry and microfluidic devices to deliver a completely implantable drug delivery mechanism, including power management, size considerations and control circuit integration [17].
Figure 5: (a) Telemetry set up (b) transmitted and (c) received signal

**THERAPEUTIC APPLICATIONS OF IDDS [12-18]**

- **Ocular disease**
  Numerous different implantable systems have been estimated to deliver sustained ocular delivery. These comprise membrane-controlled devices, implantable infusion systems and implantable silicone devices. Ocular insert having pilocarpine base and alginic acid in a drug reservoir surrounded by a release-rate controlling ethylene-vinyl acetate membrane is an example of the membrane-controlled system. The ocusert system offers an initial rupture followed by a near zero order transport of pilocarpine at 20 or 40 μg/h for a span of seven days. The device is well tolerated in adults, with suitable control of intraocular pressure and minimal side effects. However it looks to be poorly tolerated in the geriatric patients where most of the therapeutic requirement exists. Implantable evaluated for ocular cancer management include silicone rubber balloon having an anti neoplastic agent.

- **Contraception**
  Norplant; a sub-dermal implant for long-lasting transport of the contraceptive agent of levonorgestrel, recently it was approved for marketing by the FDA. The device consists of six silicone membrane capsules each having about 36 mg of levonorgestrel. The capsules are placed sub-dermally on the inside of the upper arm or the forearm in a fan-shaped pattern through a trocar from a single trocar entry point. Clinically, Norplant users have a net pregnancy rate of below 1.5 in 100 women at 4 years. At the end of 4 years 42 % of the women continued with the technique representing acceptability comparable with other techniques. Other polymer-based systems under study for contraception contain vaginal rings usually composed of silicon rubber used for 3 to 76 months often with a removal period of one week monthly to allow for menstruation; the progestaster an ethylene vinyl acetate copolymer intrauterine drug releasing device which persists for one year and suspensions of injectable microspheres or rods composed of biodegradable polymers.

- **Dental application**
  For numerous dental applications including local sustained administration of fluoride antibacterial and antibiotics, polymeric implants have been evaluated. Stannous fluoride was integrated into different dental cements for sustained release fluoride delivery. Another dispersed in the hydroxyethyl methacrylate and methyl methacrylate copolymer hydrogel coated with an outer layer of the same copolymers in differentiate so as to be rate limiting in drug release. The device, about 8 mm long and having 42 mg of fluoride in the core was attached to the buccal surface of the maxillary first molar and designed to release 0.5 mg/day of fluoride for 30 days.

- **Immunization**
  Polymeric implants are being evaluated for better immune response to antigens. The concept here is to offer pulsatile or continuous administration of the antigen over a prolonged period of time. Wise et al. evaluated immunization efficiency of ethylene-vinyl acetate copolymer pellets having bovine serum albumin as model antigen. The immune response was comparable to that achieved by two injections of bovine serum albumin in complete Freund’s adjuvant (Freund’s adjuvant is an o/w emulsion containing bacteria).

- **Cancer**
  Silicone rod implants analogous to those used for delivery of levonorgestrone have been evaluated for delivery of ethinylestradiol or testosterone propionate in persons with prostate cancer. Lupron depot produced by Takeda chemical industries is an implantation system providing one month depot release of leuprolide acetate, a synthetic...
analogue of the gonadotropin-releasing hormone (GhRH). The implant containing biodegradable microspheres made from polylactic – glycolic copolymer at 1:1 compositions having 10% leuprolide acetate for the management of prostate cancer. Zoladex produced by ICI Pharma provides one month depot release of goserelin acetate from a biodegradable implantable rod for the management of prostate cancer [4-6].

- **Narcotic antagonists**
  Naltrexone has been comprehensively evaluated in implant from long term delivery of narcotic antagonists. Naltrexone freebases its hydrochloride or the pamoate acid salt has been formulated in a various polymers and dosage forms for prolonged narcotic antagonist activity.

- **Other applications**
  Various insulin delivery systems have been formulated and evaluated for a biofeedback approach and have been described before. These are biofeedback controlled system, where the drug release rate is reliant on the body’s requirement for the drug at a specified time. From a therapeutic perspective these systems may come closest to reproducing the release from a gland for example the pancreas. Various mechanisms have been employed to attain self regulated delivery.

**I-VATION IMPLANT**

I-vation Sustained Drug Delivery implant is developed by Sur Modics. The I-vation platform offers a great deal of versatility and flexibility for formulation and pharmacokinetics control. Surmodics is developing a 5-mm long, helical coil shaped implant that’s injected into the sclera, leaving the coil end, coated with drug and a polymer matrix, sitting in the vitreous. The end cap sits under the conjunctiva, but is available for removable when necessary. The unique helical design maximizes the surface area available for drug delivery, and ensures secure anchoring of the implant against the sclera, keeping it out of the visual field and facilitating retrieval [16-18].

**Features of the I-vation Sustained Drug Delivery System**

- Sustained duration of delivery
- Targeted delivery for minimal systemic drug levels
- Coating platform compatible with a variety of drugs
- Removable and replaceable

**FUTURE PROSPECTS**

At present much research is being conducted in the region of implantable drug delivery systems. Despite this fact, much work is still required in the regions of biodegradable and biocompatible substances, the kinetics of drug release, and more improvement of present systems before many of these preparations can be used. In the future, scientists remain expectant that many of these systems can be prepared with best zero order release kinetics profiles, in vivo, over long times, allowing for prolonged use in constantly sick patients. New medicines are continuously being prepared. Several of these medications are developed from proteins and peptides which are very unstable when taken through oral route. By using new types of prolonged-release drug delivery systems, delivering such drugs at constant rates will be possible over a prolonged period of time and will exclude the necessity for multiple dosing. It is expected that in the upcoming years, improvement of new implantable systems will help cost reduction of drug treatment, increase the effectiveness of drugs, and enhance patient compliance. Most of the drugs are amenable to these types of delivery systems. With the sequencing of the human genome, biotechnology companies are rapidly developing a large number of peptide- and protein-based drugs. It is expected that in the next 10 to 20 years, protein-and peptide-based drugs will constitute more than half of the new drugs introduced into the market, and more than 80% of these protein drugs will be antibodies. These biopharmaceuticals (proteins, peptides, carbohydrates, oligo-nucleotides, and nucleic acids in the form of DNA) present drug delivery challenges because these are often large molecules that degrade rapidly in the blood stream. Moreover, they have a limited ability to cross cell membranes and generally cannot be delivered orally. Such molecules will be much more difficult to deliver via conventional routes, and injections may be the only means of delivery. The routes of administration will be dictated by the drug, disease state, and desired site of action. Some sites are easy to reach such as the nose, the mouth, and the vagina. Others sites are more challenging to access, such as the brain. Gene therapy is also likely to be one of the most exciting growth sectors as biotech companies become involved in drug delivery.

**CONCLUSION**

Recently Implantable drug delivery is one of the technology sectors that often overlooked in the development of new drug delivery by the formulation, research and development in many pharmaceuticals. Implanted drug delivery technologies have ability to reduce the frequency of patient driven dosing and to deliver the compound in targeted manner. Many product utilizing implant delivery technologies are being utilized for many therapeutics applications such as, dental, ophthalmic, oncological disease. As with any implanted material, issues of biocompatibility need to be investigated, such as the formation of a fibrous capsule around the implant and, in the case of erosion-based devices, the possible toxicity or immunogenicity of the by-products of polymer degradation. Additionally, convenient methods of triggering drug delivery from the externally controlled delivery systems need to be developed in order for them to be of practical use. These issues, coupled with the potential therapeutic benefits of pulsatile dosing regimens, should ensure that the current high level of interest in this area will extend well into the future and result in significant advances in the field of controlled drug delivery. A large number of companies are involved in the development of new drug delivery systems, which is evident by an increased number of products in the market and the number of patents granted in the recent past. Tomorrow’s drugs definitely will be more challenging in terms of the development of delivery systems, and pharmaceutical scientists will have to be ready for a difficult task ahead. Site specific, controlled release of therapeutic agents represents an attractive option for companies looking to enhance the efficacy of an existing drug product or provide additional benefit in conjunction with an implantable device. A small but well established pallet of durable and biodegradable polymeric materials provides option for delivery of potent compounds such as hormones, opioids, antibiotics and oncology drugs. Well established silicone rubber and plastic forming processes
can be leveraged to make commercial volumes of devices with excellent consistency and reproducibility. Drug delivery systems has come a long way and will continue to grow at an impressive rate. Today's drug delivery technologies enable the incorporation of drug molecules into new delivery systems, thus providing numerous therapeutic and commercial advantages.

REFERENCES